GeoVax Labs (NASDAQ:GOVX) Receives Hold Rating from D. Boral Capital

D. Boral Capital restated their hold rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report released on Thursday, MarketBeat reports.

A number of other research firms have also commented on GOVX. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Wall Street Zen downgraded GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Hold” and a consensus price target of $187.50.

GeoVax Labs Stock Up 12.2%

Shares of GOVX opened at $1.56 on Thursday. GeoVax Labs has a twelve month low of $1.26 and a twelve month high of $47.13. The stock has a market cap of $2.84 million, a PE ratio of -0.04 and a beta of 3.77. The business’s 50-day moving average price is $3.73 and its 200-day moving average price is $10.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in GeoVax Labs in the fourth quarter valued at $99,000. HRT Financial LP bought a new stake in GeoVax Labs during the fourth quarter worth about $31,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs in the 4th quarter worth about $104,000. Hudson Bay Capital Management LP bought a new position in shares of GeoVax Labs during the 3rd quarter valued at about $47,000. Finally, Armistice Capital LLC bought a new position in shares of GeoVax Labs during the 3rd quarter valued at about $253,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.